Multiple sclerosis can be inhibited or reversed using a novel gene therapy technique that stops the disease’s immune response in mouse models, University of Florida Health researchers have found.
By combining a brain-protein gene and an existing medication, the researchers were able to prevent the mouse version of multiple sclerosis. Likewise, the treatments produced near-complete remission in the animal models. The findings, which researchers said have significant potential for treating multiple sclerosis and other autoimmune disorders, are published today (Sept. 21) in the journal Molecular Therapy.
Multiple sclerosis affects about 2.3 million people worldwide and is the most common neurological disease in young adults. The incurable disorder starts when the immune system attacks the myelin sheath surrounding nerve fibers, making them misfire and leading to problems with muscle weakness, vision, speech and muscle coordination.
The researchers used a harmless virus, known as an adeno-associated virus, to deliver a gene responsible for a brain protein into the livers of the mouse models. The virus sparked production of so-called regulatory T cells, which suppress the immune system attack that defines multiple sclerosis. The gene was targeted to the liver because it has the ability to induce immune tolerance.
“Using a clinically tested gene therapy platform, we are able to induce very specific regulatory cells that target the self-reactive cells that are responsible for causing multiple sclerosis,” said Brad E. Hoffman, Ph.D., an assistant professor in the departments of pediatrics and neuroscience at the University of Florida College of Medicine.
The protein, myelin oligodendrocyte glycoprotein, was found to be effective in preventing and reversing muscular dystrophy on its own. A group of five mouse models that received the gene therapy did not develop experimental autoimmune encephalomyelitis, which is the mouse equivalent of multiple sclerosis in humans. In another experiment, all but one mouse model showed a significant reversal of the disease eight days after a single gene therapy treatment.
Hoffman said he was also encouraged by the treatment’s longevity. After seven months, the mouse models that were treated with gene therapy showed no signs of disease, compared with a group of untreated mouse models that had neurological problems after 14 days.
When the protein was combined with rapamycin — a drug used to coat heart stents and prevent organ transplant rejection — its effectiveness was further improved, the researchers found. The drug was chosen because it allows helpful regulatory T-cells to proliferate while blocking undesirable effector T-cells, Hoffman said.
Among the mouse models that were given rapamycin and the gene therapy, 71 percent and 80 percent went into near-complete remission after having hind-limb paralysis. That, Hoffman said, shows the combination can be especially effective at stopping rapidly progressing paralysis.
While researchers have established how gene therapy stimulates regulatory T cells in the liver, Hoffman said little else is known about the detailed mechanics of how that process works.
Before the therapy can be tested in humans during a clinical trial, further research involving other preclinical models will be needed, Hoffman said. Researchers also need to target the full suite of proteins that are implicated in multiple sclerosis, he added.
Still, Hoffman said he is extremely optimistic that the gene therapy can be effective in humans.
“If we can provide long-term remission for people and a long-term quality of life, that is a very promising outcome,” he said.
Learn more: Unique gene therapy prevents, reverses multiple sclerosis in animal model
The Latest on: Multiple Sclerosis
[google_news title=”” keyword=”Multiple Sclerosis” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]- Finley siblings share their fight against Multiple Sclerosis, encourages people to get checkedon April 30, 2024 at 7:33 am
According to the National Multiple Sclerosis Society, almost one million Americans live with Multiple Sclerosis (MS), an auto-immune condition that affects the central nervous system. According to ...
- ‘Liquid gold’ could bring new hope to multiple sclerosis patients, study suggests: ‘Profound benefit’on April 30, 2024 at 2:30 am
An experimental medication called CNM-Au8 — a drinkable liquid with gold nanocrystals — has shown promising results in clinical trials for improving MS symptoms. Doctors and researchers weighed in.
- Multiple sclerosis discovery could be a breakthroughon April 29, 2024 at 5:00 pm
We’ve made significant progress in developing better treatments for multiple sclerosis over the past two decades. Yet the medical community still struggles to diagnose the neurological condition, let ...
- Lisa Jarvis: This multiple sclerosis discovery could be a breakthroughon April 29, 2024 at 10:43 am
We’ve made significant progress in developing better treatments for multiple sclerosis over the last two decades. Yet the medical community still struggles to diagnose the neurological condition, let ...
- Hundreds walk in De Pere to raise awareness for Multiple Sclerosison April 28, 2024 at 9:47 am
Hundreds gathered at West De Pere High School to raise awareness for those who have been diagnosed with Multiple Sclerosis. Whether they were supporting a family member or friends, everyone who walked ...
- ‘You wouldn’t know I had it,’ woman living with Multiple Sclerosis holding awareness walkon April 26, 2024 at 6:44 pm
Happening at 9 a.m. on April 27, a walk to raise funds for the National Multiple Sclerosis Society is happening at Capaha Park ...
- Texas MS 150 bike ride for multiple sclerosis fight to raise millionson April 26, 2024 at 2:55 pm
Texas MS150 is gearing up to celebrate its 40th anniversary as thousands of cyclists raise millions of dollars for the fight against Multiple Sclerosis.
- Multiple Sclerosis Research Newson April 25, 2024 at 5:00 pm
Jan. 9, 2024 — A combination of only 11 proteins can predict long-term disability outcomes in multiple sclerosis (MS) for different individuals. The identified proteins could be used to tailor ...
- Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Programon April 22, 2024 at 4:12 am
All Patients Have Either Stabilized or Improved on Nasal Foralumab Treatment and No Patients Declined in Key Clinical Measures NEW YORK, April 22, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd.
- This Multiple Sclerosis Discovery Could Be a Breakthroughon April 20, 2024 at 5:00 am
A new blood test reveals signs of the disease years before symptoms occur. It could change how MS is diagnosed, treated and studied.
via Google News and Bing News